Study identifier:D9180C00003
ClinicalTrials.gov identifier:NCT05166889
EudraCT identifier:2021-003797-30
CTIS identifier:N/A
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (OBERON)
Chronic obstructive pulmonary disease (COPD)
Phase 3
No
Tozorakimab, Placebo
All
1099
Interventional
40 Years - 130 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Tozorakimab Dose 1 Dosing subcutaneously tozorakimab Dose 1 and placebo | Drug: Tozorakimab Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52. |
Experimental: Tozorakimab Dose 2 Dosing subcutaneously tozorakimab Dose 2 | Drug: Tozorakimab Administered subcutaneously tozorakimab Dose 2 through Week 52. |
Placebo Comparator: Placebo Dosing subcutaneously with equivalent volume to tozorakimab | Drug: Placebo Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52. |